Edition:
United States

Roche Holding AG (ROG.S)

ROG.S on Virt-X Level 1

234.15CHF
10:00am EDT
Change (% chg)

CHF-1.40 (-0.59%)
Prev Close
CHF235.55
Open
CHF235.05
Day's High
CHF236.35
Day's Low
CHF233.55
Volume
537,285
Avg. Vol
1,508,719
52-wk High
CHF252.85
52-wk Low
CHF206.35

Latest Key Developments (Source: Significant Developments)

Roche Signs Collaboration Agreement To Expand Access To Therapy Information By Integrating Insulin Data From Connected Pens To Its Open Ecosystem
Monday, 1 Oct 2018 03:00am EDT 

Oct 1 (Reuters) - Roche Holding AG ::ROCHE SIGNS COLLABORATION AGREEMENT TO EXPAND ACCESS TO THERAPY INFORMATION BY INTEGRATING INSULIN DATA FROM CONNECTED PENS TO ITS OPEN ECOSYSTEM.ROCHE - SIGNED DEVELOPMENT & COLLABORATION DEAL WITH NOVO NORDISK.  Full Article

FDA Approves Genentech's Xolair Prefilled Syringe Formulation
Friday, 28 Sep 2018 05:00pm EDT 

Sept 28 (Reuters) - Roche Holding AG ::FDA APPROVES GENENTECH'S XOLAIR (OMALIZUMAB) PREFILLED SYRINGE FORMULATION.GENENTECH SAYS NEW XOLAIR PFS FORMULATION IS EXPECTED TO BE AVAILABLE BY END OF THIS YEAR IN U.S.  Full Article

Tusk Therapeutics To Be Acquired By Roche
Friday, 28 Sep 2018 01:30am EDT 

Sept 28 (Reuters) - TUSK THERAPEUTICS::TUSK THERAPEUTICS TO BE ACQUIRED BY ROCHE.TUSK THERAPEUTICS - DEAL INCLUDES ADDITIONAL CONTINGENT PAYMENTS OF UP TO EURO 585 MILLION BASED ON MILESTONES.TUSK THERAPEUTICS LTD - UNDER TERMS OF AGREEMENT, TUSK'S SHAREHOLDERS TO GET UPFRONT CASH PAYMENT OF EURO 70 MILLION.  Full Article

Roche's Genentech Presents Interim Results Of Phase III Tecentriq Trial
Monday, 24 Sep 2018 09:45am EDT 

Sept 24 (Reuters) - Roche Holding AG ::PHASE III TRIAL OF GENENTECH'S TECENTRIQ IN COMBINATION WITH PEMETREXED AND PLATINUM-BASED CHEMOTHERAPY SHOWED REDUCED RISK OF DISEASE WORSENING OR DEATH IN A TYPE OF PREVIOUSLY UNTREATED ADVANCED LUNG CANCER.INTERIM ANALYSIS SHOWED THAT TECENTRIQ AND CHEMOTHERAPY REDUCED RISK OF DISEASE WORSENING OR DEATH (PROGRESSION-FREE SURVIVAL, PFS) BY 40 PERCENT COMPARED WITH CHEMOTHERAPY ALONE.SAYS ON TECENTRIQ TRIAL - AT THIS INTERIM ANALYSIS STATISTICAL SIGNIFICANCE HAS NOT YET BEEN MET.  Full Article

Abbvie Receives Positive CHMP Opinion Fo Chemotherapy-Free Combination Of Venclyxto With Rituximab
Friday, 21 Sep 2018 07:28am EDT 

Sept 21 (Reuters) - AbbVie Inc ::ABBVIE RECEIVES POSITIVE CHMP OPINION FOR A NOVEL, CHEMOTHERAPY-FREE COMBINATION OF VENCLYXTO® (VENETOCLAX TABLETS) WITH RITUXIMAB AS A TREATMENT WITH A FIXED DURATION FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY.ABBVIE - SAFETY PROFILE OF COMBINATION OF VENCLYXTO PLUS RITUXIMAB IS CONSISTENT WITH KNOWN SAFETY PROFILE OF EACH MEDICINE ALONE.  Full Article

Affimed To Collaborate With Genentech To Develop Novel Nk Cell Engager-Based Immunotherapeutics
Monday, 27 Aug 2018 04:10pm EDT 

Aug 27 (Reuters) - Affimed NV ::AFFIMED ANNOUNCES COLLABORATION WITH GENENTECH TO DEVELOP NOVEL NK CELL ENGAGER-BASED IMMUNOTHERAPEUTICS FOR MULTIPLE CANCER TARGETS.AFFIMED NV - TO RECEIVE $96 MILLION UPFRONT AND COMMITTED FUNDING AND IS ELIGIBLE FOR UP TO AN ADDITIONAL $5.0 BILLION INCLUDING MILESTONE PAYMENTS.AFFIMED NV - ADDITIONAL $5.0 BILLION CO MAY RECEIVE ALSO INCLUDES ROYALTIES ON SALES.  Full Article

Genentech Says FDA Grants Breakthrough Therapy Designation For Xolair (Omalizumab) For Food Allergies
Monday, 13 Aug 2018 01:00am EDT 

Aug 13 (Reuters) - Genentech Inc::FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION FOR XOLAIR (OMALIZUMAB) FOR FOOD ALLERGIES.  Full Article

Hoffmann-La Roche Ltd - Health Canada Has Approved Hemlibra (Emicizumab Injection)
Tuesday, 7 Aug 2018 08:00am EDT 

Aug 7 (Reuters) - Roche Holding AG ::HOFFMANN-LA ROCHE LIMITED - HEALTH CANADA HAS APPROVED HEMLIBRA (EMICIZUMAB INJECTION) FOR HEMOPHILIA A (CONGENITAL FACTOR VIII DEFICIENCY) PATIENTS.  Full Article

Puretech Health Announces Collaboration With Roche
Friday, 20 Jul 2018 02:00am EDT 

July 20 (Reuters) - PureTech Health PLC ::PURETECH HEALTH ANNOUNCES COLLABORATION WITH ROCHE TO ADVANCE TECHNOLOGY FOR ORAL ADMINISTRATION OF ANTISENSE OLIGONUCLEOTIDES.PURETECH HEALTH PLC - PURETECH HEALTH TO RECEIVE UP TO $36 MILLION IN UPFRONT PAYMENTS, RESEARCH SUPPORT, AND EARLY PRECLINICAL MILESTONES.PURETECH HEALTH PLC - PURETECH HEALTH ALSO ELIGIBLE TO POTENTIALLY RECEIVE OVER $1 BILLION IN DEVELOPMENT MILESTONES.  Full Article

Celgene Corp Says Phase III Impassion130 Study Met Co-Primary Endpoint Of Progression-Free Survival
Tuesday, 10 Jul 2018 07:30am EDT 

July 10 (Reuters) - Celgene Corp ::ANTI-PD-L1 IMMUNOTHERAPY PLUS ABRAXANE® SIGNIFICANTLY REDUCED THE RISK OF DISEASE WORSENING OR DEATH IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED TRIPLE NEGATIVE BREAST CANCER IN PHASE III IMPASSION130 STUDY.CELGENE CORP - PHASE III IMPASSION130 STUDY, WHICH WAS SPONSORED BY ROCHE, MET ITS CO-PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL.CELGENE - OVERALL SURVIVAL IS ENCOURAGING IN PD-L1 POSITIVE POPULATION AT INTERIM ANALYSIS, FOLLOW UP WILL CONTINUE UNTIL NEXT PLANNED ANALYSIS.CELGENE CORP - SAFETY IN TECENTRIQ PLUS ABRAXANE ARM APPEARED CONSISTENT WITH KNOWN SAFETY PROFILES OF INDIVIDUAL MEDICINES.CELGENE CORP - NO NEW SAFETY SIGNALS WERE IDENTIFIED WITH IN TECENTRIQ PLUS ABRAXANE COMBINATION.CELGENE CORP - DATA DEMONSTRATE POTENTIAL ROLE OF ABRAXANE AS PREFERRED CHEMOTHERAPY PARTNER FOR IMMUNOTHERAPY COMBINATIONS.  Full Article

BRIEF-Roche Launches Tumor Tissue Analysis Kits For Oncology Research

* ROCHE LAUNCHES NGS AVENIO TUMOR TISSUE ANALYSIS KITS FOR ONCOLOGY RESEARCH